The Ensuring Patient Access and Effective Drug Enforcement Act of 2016 is a United States federal statute enacted by the 114th United States Congress and signed into law by President Barack Obama on April 19, 2016.

It modified the Controlled Substances Act, which requires the Drug Enforcement Administration (DEA) to identify "imminent danger to the public health and safety" before suspending the registration of a manufacturer, distributor, or dispenser for controlled substances privileges.

[2] It was cosponsored by Sen. Sheldon Whitehouse [D-RI], Sen. Marco Rubio [R-FL], Sen. David Vitter [R-LA], Rep. Marsha Blackburn and Sen. Bill Cassidy [R-LA].

An earlier iteration of the bill was introduced by Rep. Tom Marino [R-PA] and passed the House of Representatives in 2015.

This United States federal legislation article is a stub.